Search

Your search keyword '"albuvirtide"' showing total 1 results
Start Over Descriptor "albuvirtide" Publisher elsevier b.v.
1 results on '"albuvirtide"'

1. Long-acting HIV fusion inhibitor albuvirtide combined with ritonavir-boosted lopinavir for HIV-1-infected patients after failing the first-line antiretroviral therapy: 48-week randomized, controlled, phase 3 non-inferiority TALENT study.

Author

Su, Bin, Yao, Cheng, Zhao, Qing-Xia, Cai, Wei-Ping, Wang, Min, Lu, Hong-Zhou, Mu, Ting-Ting, Chen, Yuan-Yuan, Liu, Li, Wang, Hui, He, Yun, Zheng, Yu-Huang, Li, Ling-Hua, Chen, Jin-Feng, Yu, Jian-Hua, Zhu, Biao, Zhao, Min, Sun, Yong-Tao, Lun, Wen-Hui, and Zhang, Yi-Hang

Abstract

• Albuvirtide (ABT) is a novel long-acting HIV fusion inhibitor. • ABT combined with LPV/r was non-inferior to LPV/r based three-drug regimen. • ABT combined with LPV/r showed a good safety profile. • ABT combined with LPV/r showed a trend of improvement in renal function. • ABT might be an interesting alternative option for HIV treatment and prevention. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results